Lymphocytic Leukemia, Acute Clinical Trials

A listing of Lymphocytic Leukemia, Acute medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

California

La Jolla California 92093

A clinical trial seeking patients for a research study for the treatment of Acute Lymphocytic Leukemia or Adult Lymphoblastic Lymphoma

Los Angeles California 90095

A clinical trial seeking patients for a research study for the treatment of Acute Lymphocytic Leukemia or Adult Lymphoblastic Lymphoma

Los Angeles California 90027

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Palo Alto California 94304

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Sacramento California 95817

A clinical trial seeking patients for a research study for the treatment of Acute Lymphocytic Leukemia or Adult Lymphoblastic Lymphoma

View More ▼

San Francisco California 94143

A clinical research study of DS-3032b for the treatment of Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

San Francisco California 94143-0324

A clinical trial seeking patients for a research study for the treatment of Acute Lymphocytic Leukemia or Adult Lymphoblastic Lymphoma

Georgia

Atlanta Georgia 30342

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Michigan

Ann Arbor Michigan 48109-5941

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Minnesota

Minneapolis Minnesota 55455

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Missouri

Kansas City Missouri 64108

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

New York

Bronx New York 10467

Patients are needed to participate in a clinical research study of Liposomal Annamycin to evaluate Acute Lymphocytic Leukemia

Buffalo New York 14263

Patients are needed to participate in a clinical research study of Liposomal Annamycin to evaluate Acute Lymphocytic Leukemia

North Carolina

Durham North Carolina 27708

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Ohio

Ohio State University Comprehensive Cancer Center
Columbus Ohio

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

View More ▼

Cincinnati Ohio 45230

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Oregon

Portland Oregon 97239

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Pennsylvania

Philadelphia Pennsylvania 19104

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Texas

Dallas Texas 75390-9034

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Houston Texas 77031

A clinical research study of DS-3032b for the treatment of Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia or Myelodysplastic Syndrome

Houston Texas 77030

A clinical trial seeking patients for a research study for the treatment of B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia or Non-hodgkin Lymphoma

Houston Texas 77030

Patients are needed to participate in a clinical research study of Liposomal Annamycin to evaluate Acute Lymphocytic Leukemia

Utah

Salt Lake City Utah 84113

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

Wisconsin

Madison Wisconsin 53705

A clinical trial to evaluate treatments using CTL019 T-cells for patients with B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia or Refractory B-cell Acute Lymphoblastic Leukemia

China

Suzhou Jiangsu 215123

A clinical trial seeking patients for a research study of anti-CD19 CAR-NK cells

Suzhou Jiangsu 215123

A Phase 1/Phase 2 clinical study for patients using PCAR-019 (anti-CD19 CAR-T cells)

Suzhou Jiangsu 215123

Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma

Italy

Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale Sant' Anna
Cona International

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia

Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST
Forli-Cesena International

Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia